Diabetes Management Guidelines

American Diabetes Association (ADA) 2013 Guidelines


Updated recommendations are available. Click here. 

Source: American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care. 2013;36(suppl 1):S11-S66.  

Jump to a section or click the arrow at the bottom right of each section 

Criteria for Diagnosis
A1C Testing
Individualized Treatment Goals
Type 2 Diabetes Risk Factors
Lifestyle Changes
Type 2 Diabetes Treatment
Insulin Therapy
Diabetes Self-Management
Obesity Treatment
Diabetes and Hypertension
Diabetes and Lipids
Diabetes and Cardiovascular Disease 
Microvascular Complications of Diabetes
Foot Care
Diabetes in the Hospital
Diabetes and Quality of Life
Diabetes and Vaccines
Diabetes and Children
Diabetes and Pregnancy
Diabetes and Older Adults
Diabetes and Cystic Fibrosis
Type 1 Diabetes Screening and Insulin Therapy 

 Type 2 Diabetes Treatment :: Hyperglycemia     Updated recommendations are available. Click here. 

Recommendations Slides
  • Metformin  
    • Preferred initial therapy (if tolerated and not contraindicated) 
  • Consider insulin therapy  
    • With or without other agents at outset in newly diagnosed patients with markedly symptomatic and/or elevated blood glucose levels or A1C 
  • Add second oral agent, GLP-1 receptor agonist, or insulin  
    • If noninsulin monotherapy at maximal tolerated dose does not achieve or maintain A1C target over 3–6 months 
  • Choice of pharmacologic therapy should be based on a patient-centered approach 
  • Consider  
    • Efficacy 
    • Cost 
    • Potential side effects 
    • Effects on weight 
    • Comorbidities 
    • Hypoglycemia risk 
    • Patient preferences  
  • Insulin therapy is eventually needed for many patients due to progressive nature of type 2 diabetes 

ADA Guidelines: Pharmacologic Therapy for Hyperglycemia in Type 2 Diabetes (1 of 2) 

ADA Guidelines: Pharmacologic Therapy for Hyperglycemia in Type 2 Diabetes (2 of 2) 
Back Lifestyle Changes  Next Insulin Therapy 

GLP=glucagon-like peptide 

The pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual package inserts for use outside of the United States. 

January 2013 

This content was created by KnowledgePoint360 Group, LLC, and was not associated with funding via an educational grant or a promotional/commercial interest.  

Back to
Clinical Guidelines 

BG Footer

Last Modified: 3/13/2014

Notice About Sponsored Content Clicking the banners below will direct you to sponsored content. KnowledgePoint360 does not endorse and bears no responsibility for sponsored content hosted on NDEI.org. For more information, please read our Editorial Policy